Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
119 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Constipation - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape. Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 10, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Constipation - Overview Constipation - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Constipation - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Constipation - Companies Involved in Therapeutics Development Albireo Pharma Inc Allergan Plc Ardelyx Inc Astellas Pharma Inc Braintree Laboratories Inc Dong-A ST Co., Ltd. EA Pharma Co Ltd Ironwood Pharmaceuticals Inc Johnson & Johnson Kissei Pharmaceutical Co Ltd NGM Biopharmaceuticals Inc RaQualia Pharma Inc Sanwa Kagaku Kenkyusho Co Ltd SK Biopharmaceuticals Co Ltd Sucampo Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd Synergy Pharmaceuticals Inc Synthetic Biologics Inc Torrent Pharmaceuticals Ltd Vanda Pharmaceuticals Inc Yuhan Corp Zensun (Shanghai) Sci & Tech Co Ltd Constipation - Drug Profiles 5-BIOP - Drug Profile Product Description Mechanism Of Action R&D Progress AJG-555 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-7663 - Drug Profile Product Description Mechanism Of Action R&D Progress Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile Product Description Mechanism Of Action R&D Progress BLI-400 - Drug Profile Product Description Mechanism Of Action R&D Progress BLI-801 - Drug Profile Product Description Mechanism Of Action R&D Progress DA-6886 - Drug Profile Product Description Mechanism Of Action R&D Progress DSP-6952 - Drug Profile Product Description Mechanism Of Action R&D Progress elobixibat - Drug Profile Product Description Mechanism Of Action R&D Progress ENT-01 - Drug Profile Product Description Mechanism Of Action R&D Progress J-027 - Drug Profile Product Description Mechanism Of Action R&D Progress KWA-0711 - Drug Profile Product Description Mechanism Of Action R&D Progress linaclotide - Drug Profile Product Description Mechanism Of Action R&D Progress linaclotide DR1 - Drug Profile Product Description Mechanism Of Action R&D Progress lovastatin - Drug Profile Product Description Mechanism Of Action R&D Progress lubiprostone - Drug Profile Product Description Mechanism Of Action R&D Progress naronapride - Drug Profile Product Description Mechanism Of Action R&D Progress NGM-282 - Drug Profile Product Description Mechanism Of Action R&D Progress plecanatide - Drug Profile Product Description Mechanism Of Action R&D Progress prucalopride succinate - Drug Profile Product Description Mechanism Of Action R&D Progress prucalopride succinate - Drug Profile Product Description Mechanism Of Action R&D Progress relenopride hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress RQ-00000010 - Drug Profile Product Description Mechanism Of Action R&D Progress SK-1202 - Drug Profile Product Description Mechanism Of Action R&D Progress tenapanor hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress YH-12852 - Drug Profile Product Description Mechanism Of Action R&D Progress ZS-06 - Drug Profile Product Description Mechanism Of Action R&D Progress Constipation - Dormant Projects Constipation - Product Development Milestones Featured News & Press Releases Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017 May 07, 2017: Synergy Pharmaceuticals to Present TRULANCE (Plecanatide) Phase 3 Data at Digestive Disease Week for the Treatment of Adults with Chronic Idiopathic Constipation with Moderate to Very Severe Bloating May 07, 2017: Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation May 01, 2017: Allergan to Present Linzess and Linaclotide Delayed Release Data at Digestive Disease Week 2017 May 01, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at Digestive Disease Week Apr 12, 2017: Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE (Plecanatide) Patent Protection Until 2032 Mar 27, 2017: Synergy Pharmaceuticals Submits Supplemental New Drug Application for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation Mar 22, 2017: Astellas Pharma Announces Launch of LINZESS Tablets 0.25mg in Japan Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program Linaclotide delayed release-1 at R&D Day 2017 Feb 07, 2017: Pivotal Phase 3 Data Results for TRULANCE (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Constipation, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Constipation - Pipeline by Albireo Pharma Inc, H2 2017 Constipation - Pipeline by Allergan Plc, H2 2017 Constipation - Pipeline by Ardelyx Inc, H2 2017 Constipation - Pipeline by Astellas Pharma Inc, H2 2017 Constipation - Pipeline by Braintree Laboratories Inc, H2 2017 Constipation - Pipeline by Dong-A ST Co., Ltd., H2 2017 Constipation - Pipeline by EA Pharma Co Ltd, H2 2017 Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 Constipation - Pipeline by Johnson & Johnson, H2 2017 Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2017 Constipation - Pipeline by RaQualia Pharma Inc, H2 2017 Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017 Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017 Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H2 2017 Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 Constipation - Pipeline by Synergy Pharmaceuticals Inc, H2 2017 Constipation - Pipeline by Synthetic Biologics Inc, H2 2017 Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017 Constipation - Pipeline by Vanda Pharmaceuticals Inc, H2 2017 Constipation - Pipeline by Yuhan Corp, H2 2017 Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017 Constipation - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
